MarketResearchNest.com adds “Drug Overdose – Pipeline Review, H2 2017” new report to its research database. The report spread across in 48 pages with table and figures in it.
Global Markets Direct’s Pharmaceutical and Healthcare disease pipeline guide Drug Overdose – Pipeline Review, H2 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.
Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260047
The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
Fab’entech SA, Insys Therapeutics Inc, Klaria Pharma Holding AB, Opiant Pharmaceuticals Inc
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260047
Featured News & Press Releases:
Aug 10, 2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization
Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent
Jun 18, 2017: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy for the Treatment of Local Anesthetic Systemic Toxicity
Jun 06, 2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose – Current Medical Research and Opinion Journal
Apr 24, 2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada
Apr 11, 2017: Ontario ministries make NARCAN Nasal Spray available to general public
Apr 10, 2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities
Mar 27, 2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray
Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose
Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel’s Co-Gel Buccal Naloxone (Exonal)
Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents
Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.
Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray
Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas
Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260047
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain